DK2001891T3 - Buprenorfinderivater samt anvendelser deraf - Google Patents

Buprenorfinderivater samt anvendelser deraf

Info

Publication number
DK2001891T3
DK2001891T3 DK07732177.6T DK07732177T DK2001891T3 DK 2001891 T3 DK2001891 T3 DK 2001891T3 DK 07732177 T DK07732177 T DK 07732177T DK 2001891 T3 DK2001891 T3 DK 2001891T3
Authority
DK
Denmark
Prior art keywords
applications
buprenorphine derivatives
buprenorphine
derivatives
Prior art date
Application number
DK07732177.6T
Other languages
Danish (da)
English (en)
Inventor
Christopher Bourne Chapleo
John William Lewis
Original Assignee
Rb Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rb Pharmaceuticals Ltd filed Critical Rb Pharmaceuticals Ltd
Application granted granted Critical
Publication of DK2001891T3 publication Critical patent/DK2001891T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
    • C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
    • C07D489/12—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK07732177.6T 2006-03-28 2007-03-27 Buprenorfinderivater samt anvendelser deraf DK2001891T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0606124.6A GB0606124D0 (en) 2006-03-28 2006-03-28 Buprenorphine derivatives and uses thereof
PCT/GB2007/001120 WO2007110636A1 (en) 2006-03-28 2007-03-27 Buprenorphine derivatives and uses thereof

Publications (1)

Publication Number Publication Date
DK2001891T3 true DK2001891T3 (da) 2013-11-04

Family

ID=36384277

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07732177.6T DK2001891T3 (da) 2006-03-28 2007-03-27 Buprenorfinderivater samt anvendelser deraf

Country Status (21)

Country Link
US (1) US7964610B2 (enExample)
EP (1) EP2001891B1 (enExample)
JP (1) JP5167446B2 (enExample)
KR (1) KR101430626B1 (enExample)
CN (2) CN104151320A (enExample)
AU (1) AU2007231133B2 (enExample)
BR (1) BRPI0709157A8 (enExample)
CA (1) CA2647417C (enExample)
DK (1) DK2001891T3 (enExample)
ES (1) ES2432169T3 (enExample)
GB (1) GB0606124D0 (enExample)
IL (1) IL193917A (enExample)
MX (1) MX2008011984A (enExample)
MY (1) MY151025A (enExample)
NZ (1) NZ570997A (enExample)
PL (1) PL2001891T3 (enExample)
PT (1) PT2001891E (enExample)
RU (1) RU2435773C2 (enExample)
TW (1) TWI501969B (enExample)
WO (1) WO2007110636A1 (enExample)
ZA (1) ZA200807614B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2549115T3 (es) 2006-09-22 2015-10-23 Zynerba Pharmaceuticals, Inc. Profármacos de buprenorfina administrables por vía transdérmica y composiciones resistentes al consumo excesivo de los mismos
US20110053971A1 (en) * 2008-04-24 2011-03-03 Janssen Pharmaceutica Nv Nalmefene di-ester prodrugs
FR2975912B1 (fr) 2011-05-30 2013-06-14 Flamel Tech Sa Composition a liberation controlee de buprenorphine
CA3002082A1 (en) * 2015-10-26 2017-05-04 Orphomed, Inc. Ethylene glycol ether of buprenorphine
EP3426234A1 (en) 2016-03-09 2019-01-16 Indivior UK Limited Abuse-resistant pharmaceutical formulations
PL3512518T3 (pl) 2016-09-13 2023-03-27 Alar Pharmaceuticals Inc. Preparaty buprenorfiny o przedłużonym uwalnianiu
WO2019064026A1 (en) 2017-09-29 2019-04-04 Orexo Ab NEW PHARMACEUTICAL COMPOSITIONS
TWI838372B (zh) 2018-05-11 2024-04-11 昱展新藥生技股份有限公司 丁基原啡因衍生物之長效注射劑型及結晶型
GB201904767D0 (en) 2019-04-04 2019-05-22 Orexo Ab New pharmaceutical compositions
WO2023102489A1 (en) * 2021-12-03 2023-06-08 Board Of Regents Of The University Of Nebraska Compounds, nanoparticles, and pharmaceutical compositions for the treatment of drug addiction
CN116283893B (zh) * 2023-03-22 2024-04-26 阜阳欣奕华制药科技有限公司 硫代羟基乙酸酐的制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4668685A (en) * 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
GB8728294D0 (en) * 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
US5985880A (en) * 1996-06-05 1999-11-16 Delta Pharmaceuticals Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
US5750534A (en) * 1994-03-16 1998-05-12 National Science Council Nalbuphine esters having long acting analgesic action and method of use
US6004969A (en) * 1996-04-15 1999-12-21 National Science Council Transdermal delivery of buprenorphine preparations
KR100204659B1 (ko) * 1996-05-28 1999-06-15 강재헌 신규한 부프레노핀계 진통제용 화합물
US6225321B1 (en) * 1997-06-05 2001-05-01 Oliver Yoa-Pu Hu Long analgesic acting nalbuphine polyester derivative and method of use
CN1150895C (zh) 1998-11-13 2004-05-26 杰格研究股份公司 用于吸入给药的干粉
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
SI2283842T1 (sl) * 2000-02-08 2015-07-31 Euro-Celtique S.A. Oralne formulacije opioidnih agonistov, varne pred zlorabo
WO2003026743A2 (en) * 2001-09-26 2003-04-03 Penwest Pharmaceuticals Company Opioid formulations having reduced potential for abuse
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
US7776314B2 (en) * 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
EP1554290B1 (en) * 2002-10-25 2009-09-30 Euro-Celtique S.A. Analogs and prodrugs of buprenorphine
DE10250084A1 (de) * 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10250087A1 (de) 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20050186139A1 (en) * 2002-10-25 2005-08-25 Gruenenthal Gmbh Abuse-proofed dosage form
US20050191244A1 (en) * 2002-10-25 2005-09-01 Gruenenthal Gmbh Abuse-resistant pharmaceutical dosage form
RU2215741C1 (ru) * 2002-11-05 2003-11-10 Открытое Акционерное Общество "Международная Научно-Технологическая Корпорация" Сложные эфиры n-замещенных 14-гидроксиморфинанов и способ их получения
CN1263760C (zh) * 2002-11-12 2006-07-12 财团法人奇美医院 新颖的丁丙诺啡酯衍生物及其制备方法，以及长效作用镇痛药学组合物
ATE382050T1 (de) * 2002-11-25 2008-01-15 Chi Mei Foundation Medical Ct Buprenorphinesterderivate, verfahren zu ihrer herstellung, und langwirksame analgetische arzneimittel
JP2004175706A (ja) * 2002-11-26 2004-06-24 Chi Mei Foundation Medical Center 新規なブプレノルフィンのエステル誘導体及びそれらの調製方法、及び長時間効力持続性鎮痛薬剤組成物
TW200500067A (en) * 2003-01-21 2005-01-01 Control Delivery Sys Inc Salts of codrugs and uses related thereto
WO2004071491A1 (en) * 2003-02-04 2004-08-26 Chrysalis Technologies Incorporated Aerosol formulations and aerosol delivery of buspirone, buprenorphine, triazolam, cyclobenzaprine and zolpidem
US7195882B2 (en) * 2003-06-03 2007-03-27 Roche Diagnostics Operations, Inc. Monoclonal antibodies specific for buprenorphine and metabolites thereof
WO2005009377A2 (en) * 2003-07-23 2005-02-03 University Of Kentucky Research Foundation Novel oral bioavailable prodrugs
US7589233B2 (en) * 2003-07-29 2009-09-15 Signature R&D Holdings, Llc L-Threonine derivatives of high therapeutic index
US7220842B2 (en) * 2004-04-05 2007-05-22 Dade Behring Inc. Immunoassays for buprenorphine and norbuprenorphine

Also Published As

Publication number Publication date
GB0606124D0 (en) 2006-05-03
KR101430626B1 (ko) 2014-08-18
BRPI0709157A8 (pt) 2018-04-24
TWI501969B (zh) 2015-10-01
ES2432169T3 (es) 2013-12-02
AU2007231133B2 (en) 2011-09-01
EP2001891B1 (en) 2013-07-24
PL2001891T3 (pl) 2014-03-31
CN101410402A (zh) 2009-04-15
CN104151320A (zh) 2014-11-19
JP2009531406A (ja) 2009-09-03
JP5167446B2 (ja) 2013-03-21
US7964610B2 (en) 2011-06-21
US20100234412A1 (en) 2010-09-16
RU2435773C2 (ru) 2011-12-10
IL193917A (en) 2014-12-31
TW200806672A (en) 2008-02-01
MX2008011984A (es) 2008-10-03
ZA200807614B (en) 2009-10-28
BRPI0709157A2 (pt) 2011-06-28
AU2007231133A2 (en) 2008-10-16
CA2647417C (en) 2014-09-23
NZ570997A (en) 2011-08-26
AU2007231133A8 (en) 2011-08-25
PT2001891E (pt) 2013-10-30
MY151025A (en) 2014-03-31
RU2008142527A (ru) 2010-05-10
WO2007110636A1 (en) 2007-10-04
AU2007231133A1 (en) 2007-10-04
EP2001891A1 (en) 2008-12-17
KR20080105124A (ko) 2008-12-03
CA2647417A1 (en) 2007-10-04

Similar Documents

Publication Publication Date Title
BRPI0716300A2 (pt) Artigo e mistura
BRPI0716500A2 (pt) Projétil e método de direcionamento de projétil
EP2087096A4 (en) MODIFIED CYANOBACTERIA
PT2029145T (pt) Compostos pirrolopirimidina e suas utilizações
DE602007012130D1 (de) Modifizierte flavin-adenin-dinucleotid-abhängige glucose-dehydrogenase
BRPI0815588A2 (pt) Compostos de poliorganossiloxano-poliuréia e/ou de poliorganossilo-xano-poliuretano
DE602007002544D1 (de) Nuancierungsmittel
DE602007008423D1 (de) Flüssigkeitshärtung
DE602007009267D1 (de) Reifenaufblasverfahren
HRP20141261T1 (xx) Spojevi tioninija i njihove uporabe
ATE546437T1 (de) Aminomethyl-4-imidazole
BRPI0817844A2 (pt) Derivados de 3-alcóxi-1-fenilpirazol e pesticidas
ZA200807614B (en) Buprenorphine derivatives and uses thereof
CR10430A (es) Aminothiazoles and their uses
DE112007003147A5 (de) Rohr-Biegevorrichtung
EP2044097A4 (en) Modified ribonucleases
DE602007012951D1 (de) Verbundschraubenausräumtür
DE502006006067D1 (de) Ng
DK2068922T3 (da) Anti-IL-13Ralfa1-antistoffer samt deres anvendelser
EP2054074A4 (en) MODIFIED ERYTHROPOIETIN
DE502007005975D1 (de) Wischblatt
FI20060665A0 (fi) Poikkeavuuden havaitseminen
DE602006011371D1 (de) Infrarot-eindringdetektionseinrichtung
FI20060691A0 (fi) Laitekotelointi
EP2191283A4 (en) TEMPORAL DIMENSIONAL REFLECTOMETRY SYSTEM AND METHOD OF USE